Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04703244 · ClinicalTrials.gov registry record
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
A clinical trial of Breast Cancer and Residual, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 999
- Enrollment target
- 1
- Study location
NCT04703244 is a study of Breast Cancer and Residual that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 999 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04703244, a study of Breast Cancer and Residual, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 999 participants
- Enrollment target
- 1
- Study location
Study Summary
Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.
Conditions Studied
Interventions
- PROCEDURE chemotherapy or endocrine therapy for breast cancer
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 999 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2042-01-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04703244
The ClinicalTrials.gov registry entry for NCT04703244 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 999 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which chemotherapy or endocrine therapy for breast cancer is the first listed.
NCT04703244 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04703244 about?
NCT04703244 is a clinical study titled "Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer". Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.
What is the current status of trial NCT04703244?
This trial is currently recruiting. The enrollment target is 999 participants. The study started on 2021-01-13. Estimated completion is 2042-01-15.
What conditions does trial NCT04703244 study?
This clinical trial studies the following conditions: Breast Cancer, Residual.
What interventions are being tested in trial NCT04703244?
The interventions under investigation include: chemotherapy or endocrine therapy for breast cancer (PROCEDURE).
Who is sponsoring clinical trial NCT04703244?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04703244 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.